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Summary: Using a highly sensitive enzyme immunoassay (EIA) System, we determined creatine kinase isozymes,
namely creatine kinase-MB and creatine kinase-MM, in sera of patients suffering from primary hypothyroidism with
concomitant signs of myocardial affections before and during treatment. After oral administration of Ζ,-thyroxine, the
augmented mass concentrations of serum creatine kinase-MB and creatine kinase-MM, and the increased catalytic
activity concentrations of serum total creatine kinase and creatine kinase-MB gradually decreased in inverse pro-
portion to the increased concentrations of serum triiodothyronine (T3) and thyroxine (T4). By the 6th to 8th week
after treatment, the elevated levels of serum total creatine kinase and creatine kinase-MB catalytic activity concen-
trations (assayed by a routine method) and serum creatine kinase-MM mass concentrations (assayed by EIA)
declined to normal vahies, while serum T3, T4, and thyroid stimulating hormone attained normal values. Serum
creatine kinase-MB mass concentrations (assayed by EIA), however, still remained at the higher level, without
complete recovery from myocardial damage, s show by electrocardiogram (ECG).
These data indicate that metabolic distortion still exists in the myocardium, s revealed by the high creatine kinase-
MB mass concentration, espeei lly s assayed by EIA, even though the plasma levels of thyroid hormones had
returned to normal.
Introduction concentration of creatine kinase-MB and creatine ki-
nase^MM during treatment of hypothyroidism, using a
Creatine kinase plays an importantrole in energymetab-
 Wghly sensitiye enzyme immunoassay system which
olism in muscles. Three isozymes are recognized, and
 was ablp to detect lower semm levels of creatine ^ ^,
these exhibit tissue-specificity in their mode of distribu-
 M (9> 10). tfais confirmed that serum creatine kinase-
tion; the BB form is found in the brain, the MB form in
 MB levels st l remained hjgh, even though serum con-
the heart, and the MM form in the skeletal muscles (l,
 eentrations of thyroid stimulating hormone and thyroid
2). Isozyme, creatine kinase-MB, is easily released from hormones, and the serum catalytic activity concentra-
cardiac muscle after acute myocardial infarction (3-5).
 tions of total creatine kinase and creatine kinase-MB
Hypothyroidism induces the elevation of serum creatine
 measured by the routine method were normalized.
kinase, aspartate aminotransfer se and lactate dehydro-
genase activity concentrations, accompanied by electro-
cardiographic changes and signs of distorted skeletal Materials and Methods
muscle metabolism (6, 7). Gradual recovery from these .
u Δ. L ·Λΐ- ι u The subjeets for this study were 20 patients (aged from 4s to 67
changes occurs after thyroid hormone replacement ther-
 years) at our unive^ity hospital, with rclativcly scvere hypothy-
apy (8), In this study, we determined the serum mass roidism due to chronic thyroiditis (12 cases) and idiopatliic 1ι>φα-
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thyroidism (8 cases) associated'vvith abnormal elevation of creatine
kinase isozyme catalytic activity concentrations. These patients re-
vealed high serum catalytic activity concentration of total creatine
kinase and high serum mass concentration of creatine kinase-MB.
In all these patients, abnormal ECG findings (bradycardia and ST
changes) were noted, suggesting myocardial damage due to hypo-
thyroidism, äs shown by cardiac muscle biopsy (11). None of tihe
patients showed evidence of other cardiac diseases. Serum samples
were collected every 2 weeks for 8 weeks after the administration
of L-thyroxine (up 50 g/day every 1.5 weeks). We were able to
check ECGs in 18 of these 20 patients during the course of the
treatment. Blood samples were taken from a cubital vein in the
early morning after fasting, then centrifuged to obtain the sera,
vvhich were stored at -40 °C until use.
For the determination of creatine kinase isozyme mass concentra-
tion, we used a highly sensitive enzyme immunoassay (EIA), de-
veloped by Kalo et al. (9), which has the capacity to detect a lower
concentration of creatine kinase isozymes than the minimal con-
centration detectable by a routine method. A routine method for
the determination of creatine kinase-MB catalytic activity concen-
tration was reported previously (12). The principle of this method
is the direct measurement of creatine kinase-B subunit at 37 °C by
inhibiting M subunits with M subunit antibody. A method for total
creatine kinase was reported by Szasz et al. (13). Total creatine
kinase catalytic activity concentration was measured at 37 °C,
using the Technicon RA System (Technicon Instruments Corpora-
tion, New Vork, USA). Creatine kinase-MB catalytic activity con-
centration is within 9% of total creatine kinase activity. The normal
ranges reported in these papers were confirmed in our laboratory,
using 50—60 samples from healthy subjects.
Results
Changes öf serum creatine kinase-MB and creatine ki-
nase-MM mass concentrations and total creatine kinase
and creatine kinase-MB catalytic activity concentration
were analysed during the treatment of hypothyroid pa-
tients.
The augmented mass concentrations of serum creatine
kinase-MB and creatine kinase-MM assayed by EIA and
the increased catalytic activity concentration of serum
total creatine kinase and creatine kinase-MB assayed by
a routine method decreased gradually in inverse propor-
tion to the increase in serum tniodothyronine (T3) and
thyroxine (T4) levels. By the 6th-8th week after treat-
ment, serum catalytic activity concentrations of total
creatine kinase and creatine kiiiäse-MB assayed by a
routine method, and serum mass concentrations of cre-
atine kinase-MM assayed by EIA reached normal values
(fig. 1), corresponding to the normalization of serum T3,
T4, arid thyrotropin levels (tab. 1). However, at this
point, serum mass concentrations of creatine kinase-MB
assayed by EIA were very low compared with those of
total creatine kinase; they were hard to detect by a rou-
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Fig. l Changes in serum levels of total creatine kinase (a) and the normal ränge of creatine kinase-MB assayed by a routine
creatine kinase isozymes (b) and (c) in hypothyroid patients during method.
treatment. Valües are the mean ± SE of 15 patients. o-e: creatine kinase-MB assayed by a highly sensitive enzyme
Shaded areas ESI show the normal ränge in a highly sensitive en- immunoassay;
zyme immunoassay. In panel c, the oblique line area ü shows 0—O: creatine kinase-MB assayed by a routine method.
Tab. l Serum concentrations of thyrotropiri and thyröid hormones in 20 hypothyroid patients during
the oral administration of L-thyroxine.
Weeks after treatment 0 2 4
Thyrotropin [mU/1] (0.4-3.5)
Triiodothyronine |^ g/l] (54-105)
Thyroxine ^g/l] (0.7-1.6)
153 ± 11
19 ± 3
0.40 ± 0.08
65.6 ±5.2
38 ± 7
0.63 ± 0.10
32.6 ±4.2
51 ± 8
0.90 ±0.1 5
11.2 ±3.2
81 ± 11
0.97 ±0.14
3.2 ± 0.8
86 ± 12
1.20 ± 0.18
The valües are the mean ± SE.
The valües in parentheses present the normal ränge in 50 healthy persons measured in oür üaboratory. * »
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Tab. 2 Changes in serum concentrations of thyroid hormones, thyrotropin and creatine kinase iso-
zymes and changes of ECO during the treatmeht of hypothyroid patients (case l and 2).
Case 1.
Weeks after treatment
Triiodothyronine (μg/l)
Thyroxine fog/l)
Thyrotropin (mU/1)
Total creatine kinase (U/l)
Creatine kinase-MM (μg/l) (S)
Creatine kinase-MB (μβ/l) (S)
Creatine kinase-MB (U/l) (R)
ECG
ECG in V5
0.7-1.6
 μβ/1,
55-128μδ/1,
0.4-3.5 mU/1,
< 190 U/l,
Reference ranges: Triiodothyronine
Thyroxine
Thyrotropin
Total creatine kinase
Creatine kinase-MM
Creatine kinase-MB 0.36—3.37 μg/l (S = sensitive enzyme immunoassay) and
< 20 U/l (R = routine assay).
Asterisks show abnormal values.
MD: myocardial damage.
Case 2.
Weeks after treatment 0
Triiodothyronine ^g/l) 0.4*
Thyroxine (μg/l) 10*
Thyrotropin (mU/1) 180*
Total creatine kinase (U/l) 920*
Creatine kinase-MM (|ig/l) (S) 276*
Creatine kinase-MB fag/I) (S) 13.6*
Creatine kinase^MB (U/l) (R) 50*
ECG MD
—
2
0.4*
18*
170*
605*
195*
5.5*
31*
MD
- ·τ — Ξ^ ii^iiiiivv
«— — — ^ — _.__.···.·
=^T~H::i::h·:
r.:Irr
i:
i':i
: .
:
ir
-ji
4 6
0.5* 0.7
40 60
84* 6.0
305* 98
157* 32
3.5* 1.8
18 6
MD N
;:r ::..:.:.nr.:t::::— rrrrnr.irrr.
8
0.9
92
2.5
59
33
2.1
7
N
:—:-:= . ; .:.. .:.
Reference ranges: Triiodothyronine 0.7-1.6 μ|/1,
Thyroxine 55 -128 μ£/1,
Thyrotropin 0.4-3.5 mU/1,
Total creatine kinase < 190 U/l,
Creatine kinase-MM 23.5-114.6 μο/\9
Creatine kinase-MB 0.36-3.37 μg/l (S ?=
< 20 U/l (R = routine assay).
Asterisks show abnormal values.
MD: myocardial damage.
sensitive enzyme immunoassay) and
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tinc method, but could be measured by a highly sensitive
method; they still remained high in 12 patients (flg. Ic).
In these latter 12 patients, the myocardial damage shown
in the ECGs had not improved (7 cases of chronic thy-
roiditis, 5 cases of idiopathic hypothyroidism). The re-
presentative case is shown in table 2 (case 1). In the
other six patients (3 cases of chronic thyroiditis, 3 cases
of idiopathic hypothyroidism) who were checked by
ECGs, the ST changes in ECGs subsided when the se-
rum levels of creatine kinase-MB (assayed by EIA, not
by a routine method) reached normal values during the
course of the treatment (the representative case is shown
in tab. 2, case 2). High creatine kinase-MB mass concen-
trations assayed by EIA declined to normal levels by
the 12-14th week after treatment, concomitantly with
normalization of the ECG (data not shown). The
changes in serum catalytic concentfations of aspartate
aminotransferase and lactate dehydrogenase in these pa-
tients paralleled changes in the catalytic activity concen-
tration of total creatine kinase and the mass concentra-
tion of creatine kinase-MM.
Discussion
Since the distribution of creatine kinase isozymes is tis-
sue-specific, several investigators (l, 2) have analysed
serum levels and tissue contents of creatine kinase-iso-
zymes, in order to estimate tissue damage in hypothy-
roid patients. It has been reported that in hypothyroid-
ism, the isozyme analysis of elevated creatine kinase
levels shows primarily an MM pattern, although a trace
MB fraction could be seen, suggesting that the source
of the creatine kinase elevations was skeletal muscle
(14). Our study clarified the fact that changes in serum
total creatine kinase and creatine kinase-MB catalytic
activity concentration and serum creatine kinase-MM
and creatine kinase-MB mass concentrations correlate
reciprocally with serum levels of thyroid hormones.
However, the serum level of creatine kinase-MB, mea-
sured by a highly sensitive method, were still high. This
creatine kinase-MB may arise from heart muscle rather
than skeletal muscle, because the serum mass concentra-
tion of creatine kinase-MM, which represented more
than 90% of creatine kinase-isozymes, was normalized.
The ECG changes persisted when serum levels of thy-
roid hormones had been normalized by thyroid hormone
replacement therapy. The change in creatine kinase-MB
rnass concentrations rnay be mainly due to heart tissue,
while the change in creatifte; kinase-MM mass concen-
trations is mainly due to leg muscle tissue. It can be
speculated that since changes of creatine kinase-MM
precede those of creatine kinase-MB, recovery proceeds
more rapidly in skeletal muscle than in myocardium. In
addition to acute myocarditis and cardiomyopäthy (15),
which cause reversible ECG changes and cardiac en-
zyme abnormalities in the absence of myocardial infarc-
tion, hypothyroid patients also frequently display revers-
ible myocardial damage associated with elevated cardiac
enzyme activities. In patients with hypothyroidism and
irreversible ECG changes induced by irreversible
chronic myocardial damage, the reversible cardiac en- ;,
zyme abnormality, such äs creatine kinase-MB, may be ;
önly a usefiil marker for hypothyroid^-induced myocar- j
dial damage. l]
Latner et al. (16) have confirmed that creatine kinase- {
MB isozyme concentrations in the serum of uraemic pa- ;|
tients, measured by chemiluminometric immunoassay, jj
correlated with those determined by an electrophoretic ·
method. Eisenberg et al. (17) have also reported that the
rates of decrease in creatine kinase-MB catalytic activity
and mass concentration äfter attaining their peak values
were comparable in plasma samples from patients with
myocardial infarction. Therefore, there may be no differ-
ence in the decay of creatine kinase-MB catalytic activ-
ity and mass concentration, or in the different sübspecies
of creatine kinase-MB molecules, so that the data shown
in figure Ic cannot be interpreted ön this basis.
When serum levels of creatine kinase-MB (measured by
a highly sensitive method (9, 18) in hypothyroid patients
treated with thyroid hormones) still remain high, even
though serum levels of thyroid hormones, routinely
measured total creatine kinase and creatine kinase-MB
catalytic activity concentrations and EIA-assayed ere-
atine kinase-MM mass concentrations have become nor-
mal, careful attention müst be paid to the cärdioVascülaf
System of the patient.
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